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Abstract
Alzheimer’s disease (AD) and prion diseases carry a significant inflammatory component.
The astrocytic overexpression of CCAAT/enhancer-binding protein delta (C/EBPD) in
prion- and AD-affected brain tissue prompted us to study the role of this transcription factor
in murine model systems of these diseases. Ablation of C/EBPD had neither in the AD
model (APP/PS1double transgenic mice) nor in the prion model (scrapie-infected C57BL/6
mice) an influence on overt clinical symptoms. Moreover, the absence of C/EBPD did not
affect the extent of the disease-related gliosis. However, C/EBPD-deficient APP/PS1 dou-
ble transgenic mice displayed significantly increased amyloid beta (Abeta) plaque burdens
while amyloid precursor protein (APP) expression and expression of genes involved in beta
amyloid transport and turnover remained unchanged. Gene expression analysis in mixed
glia cultures demonstrated a strong dependency of complement component C3 on the pres-
ence of C/EBPD. Accordingly, C3 mRNA levels were significantly lower in brain tissue of C/
EBPD-deficient mice. Vice versa, C3 expression in U-373 MG cells increased upon trans-
fection with a C/EBPD expression vector. Taken together, our data indicate that a C/EBPD-
deficiency leads to increased Abeta plaque burden in AD model mice. Furthermore, as
shown in vivo and in vitro, C/EBPD is an important driver of the expression of acute phase
response genes like C3 in the amyloid-affected CNS.
Introduction
CCAAT/enhancer-binding protein delta (C/EBPD) is a member of the CCAAT/enhancer-
binding protein (C/EBP) family of transcription factors, which carry a conserved basic-leucine
zipper domain directing dimerization and DNA binding. It is involved in the regulation of a
diverse range of biological processes like inflammation and cellular differentiation. Basal C/
EBPD expression levels are typically low but are highly inducible by multiple stimuli [1]. In the
periphery its role in the regulation of acute phase genes like complement component C3 and
antichymotrypsin and, more generally, in innate immunity has been extensively studied. E.g.
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LPS stimulation of TLR-4 on macrophages rapidly induces C/EBPD transcription, which in
turn is critical for achieving maximal transcription levels of numerous other genes including
IL-6 [2]. Furthermore, C/EBPD is inducible by cytokines like IL-1beta and TNFalpha [3]. Con-
versely, C/EBPD promotes expression of these pro-inflammatory cytokines thereby potentially
forming an autocrine pro-inflammatory feedback mechanism [1]. Given that C/EBPD acts in a
self-promoting manner it could potentially contribute to the undesirable prolongation of tran-
sient innate immune responses. Activating transcription factor 3 (ATF-3) was identified as
transcriptional repressor to limit such C/EBPD-driven responses in the periphery once the
inducing bacterial pathogen has been cleared [2].
In the healthy brain C/EBPD was suggested to play a role in the consolidation of long-term
memory and to regulate the expression of glycogen metabolism-related enzymes in astrocytes
[4, 5]. In the diseased brain C/EBPD was implicated in the progression of neuroinflammation
[6–9]. In fact, astrocytic C/EBPD is inducible by pro-inflammatory cytokines like IL-1 [10, 11]
and TNFalpha [12]. Accordingly, astrocytic C/EBPD overexpression was observed in brain tis-
sue obtained from AD patients [7], as well as in a murine AD-model [10], and scrapie-infected
mice [13]. Moreover, the pronounced induction of C/EBPD expression following traumatic
brain injury (TBI) was suggested as link between TBI and the increased risk for subsequent
development of AD [14]. In fact, potential target genes of C/EBPD like C3 are overexpressed in
AD and have been implicated as disease modifiers.
To gain more insights into functions of C/EBPD in chronic neurodegeneration we investi-




All animal experiments were approved by the local animal welfare authority (Landesamt für
Gesundheit und Soziales, Berlin, Germany). C/EBPD-deficient (C/EBPD(-/-)) C57BL/6 mice
[15] were obtained from E. Sterneck (National Cancer Institute, Frederick, USA) and outbred
to yield C/EBPD(-/-) and C/EBPD(+/+) mice. Transgenic APP/PS1APPSwe/PS1dE9 (APP/PS1)
mice (background C57BL/6) [16], carrying the human amyloid precursor protein (APP) 695
with the Swedish double mutation K595N/M596L and the human PS1 gene with the exon 9
deletion mutation were from The Jackson Laboratory (stock no. 004462). APP/PS1 mice defi-
cient for C/EBPD (APP/PS1 x C/EBPD(-/-)) were generated by crossbreeding APP/PS1 mice
with C/EBPD(-/-) mice. Genotyping of C/EBPD(-/-) mice was performed by PCR using the fol-
lowing primers: Wild type (C/EBPD(+/+)) mice: CTCCAGGCTTGGACGGCTAAGTAGG (for-
ward) and AAGTTGGCTGTCACCTCGCC (reverse) to detect a 205 bp fragment
of the C/EBPD coding region; C/EBPD(-/-) mice: GCTCCAGACTGCCTGG
GAAAAGC (forward) and CAGTCCAGTGCCCAAGCTGC (reverse) to amplify a
305 bp fragment of the pGKneo promoter and 3’UTR of C/EBPD. The primer
sequences for genotyping the APP/PS1 mice were: GACTGACCACTCGAC
CAGGTTCTG (forward) and CTTGTAAGTTGGATTCTCATATCCG (reverse) to yield a 350
bp fragment.
The health status of AD mice was checked regularly including determination of body
weights, and nest building was assessed as described elsewhere [17].
Scrapie infections were performed as previously described [18] using brain homogenates
prepared from terminally ill scrapie strain 139A-infected mice. All animals were monitored
thrice weekly for development of clinical symptoms in the course of scrapie disease
progression.
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Tissue collection
Mice were sacrificed at 6, 9, 12, and 18 months of age by cervical dislocation. Brains were
removed and divided sagitally. One hemibrain was snap frozen in liquid nitrogen and stored at
-80°C before further Western blot, while the other hemibrain was fixed in paraformaldehyde
(4% for 24 h and 2% for additional 2–14 days) at 4°C followed by dehydration and embedding
in paraffin.
Western blot analysis
For Western blot detection of Abeta, brains were homogenized in sterile phosphate buffered
saline (PBS) containing protease inhibitor (Complete ULTRA Tablets; Roche) and phosphatase
inhibitor (phosphatase inhibitor cocktail 2; Sigma-Aldrich). 10% (w/v) homogenates were son-
icated three times for 5 s and centrifuged at 3000 x g for 5 min at 4°C as previously described.
The supernatants were collected and stored at -80°C for further analysis. For the extraction of
insoluble subcellular fractions, an amount of supernatant was ultra-centrifuged at 100.000 x g
for 1 h at 4°C. The pellet was resuspended in 1% PBS/ sodium dodecyl sulfate (SDS) solution,
sonicated three times for 5 s and ultra-centrifuged at 100000 x g for 1 h at 4°C. The supernatant
was removed and the pellet was resuspended in 88% formic acid solution (Merck). The sample
was sonicated for 5 min at 4°C followed by shaking at 23°C and 600 rpm for 4 h and then
stored frozen at -80°C until use.
Protein concentration was quantified by BCA protein assay (Thermo Fisher Scientific).
Samples were run on 10% or 12.5% SDS-PAGE gels except for Abeta detection, where the sam-
ples were loaded on modified SDS-PAGE gels as described previously [19]. Abeta protein loads
were detected with anti-Abeta 6E10 antibody (SIG-39300; Covance), microglia with anti- ion-
ized calcium-binding adapter molecule 1(Iba1) antibody (PA5-18039; Thermo Fisher Scien-
tific), astrocytes with anti-glial fibrillary acidic protein (GFAP) antibody (Z0334; Dako),
complement component C3 with anti-C3 antibody (ICN55444; Thermo Fisher Scientific), and
beta-actin (loading control) with anti-beta-actin antibody (A5441; Sigma-Aldrich). Misfolded,
disease-specific PrPSc protein loads were detected using monoclonal mouse 4H11 antibody
[20], kindly provided by H. Schätzl (Department of Comparative Biology and Experimental
Medicine, Faculty of Veterinary Medicine, University of Calgary, Calgary, Canada).
Anti-goat AP-conjugated (705-055-147; Dianova) or anti-mouse AP-conjugated (D0486;
Dako) secondary antibodies were used for Abeta protein and microglia or astrocytes and com-
plement C3 or beta-actin detection, respectively. Signal was detected by chemiluminescence
using the CDP-Star substrate (Life Technologies). All blots were analyzed using Quantity One
software (Bio-Rad).
Histology and Immunohistochemistry
Serial sagittal sections (6 μm) were cut from paraffin-embedded brains to evaluate the plaque
burden and the amount of activated astrocytes and microglia. Plaque staining with Congo red
(Sigma-Aldrich) was performed as described previously [21, 22]. Abeta plaques were also
detected immunohistochemically using anti-Abeta 4G8 antibody (SIG-39220; BioLegend) after
pretreating tissues in 70% formic acid solution for 10 min. Activated astrocytes were detected
using GFAP antiserum (Z0334; Dako) and microglia were stained with the Iba-1 antibody
(016–20001; Wako Chemicals). Secondary antibodies were either anti-mouse IgG (RPN1001;
GE Healthcare) or anti-rabbit IgG (RPN1004; GE Healthcare). Staining was visualized using
streptavidin-horseradish peroxidase conjugate (RPN1231; GE Healthcare), followed by 3,3'-
Diaminobenzidine (DAB) as substrate.
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For the quantification of amyloid plaque loads as well as numbers of activated astrocytes
and microglia activation, 6 μm brain slices were examined under a Zeiss Axioskop-40 micro-
scope and images were acquired at 100X magnification with a Zeiss Axiocam high resolution
digital color camera. For each animal, three sections in the premotor cortex (M2) and in the
hippocampal area [23] were analyzed using ImageJ software (National Institutes of Health,
USA). Pictures were converted to 8-bit black and white and a fixed intensity threshold was
applied defining the specific Congo red or DAB staining.
RNA extraction and real-time PCR
Total RNA was isolated from brains using TRIzol reagent (Life Technologies), and from cell
cultures using the InviTrap Spin Cell RNAMini Kit (Stratec) according to the manufacturers’
protocols. Total RNA was reverse transcribed using the First-Strand cDNA synthesis kit (Qia-
gen). Real-time PCRs were performed on ABI 7500 (Applied Biosystems) and MX3000P (Stra-
tagene) real-time PCR system cyclers using gene-specific TaqMan gene expression assays
(Tables 1 and 2) and gene specific primers (Tables 3 and 4) in combination with a SYBR green
dye-based gene expression detection kit (Life Technologies). Data analysis was performed by
applying the delta-delta Ctmethod [24]. Two endogenous housekeeping genes, glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) and beta-actin, were quantified in parallel to
compensate for variations in amounts of input RNA and efficiencies of reverse transcription
and results were normalized to these averaged endogenous housekeeping gene values.
Cell culture and isolation of primary mouse mixed glia cells
Mixed glia cultures were established using previously described methods [25, 26] with few
modifications. In brief, brains from 1- to 3-d-old neonatal C/EBPD(-/-) and WTmice were
removed and cerebral cortices, cerebelli and brain stems were collected in Hank's Balanced Salt
Solution (HBSS) with Mg2+ and Ca2+ (Life Technologies). Tissues were digested in 0.1% tryp-
sin-EDTA (Biochrom) in Mg2+/Ca2+-free HBSS for 12 min at 37°C. The digestion was stopped
by adding culture medium (DMEM with high Glucose (41966–029; Life Technologies) supple-
mented with 10% FCS (Biochrom), 100 IU/ml penicillin and 100 mg/ml streptomycin sulfate
(Biochrom), and 0.1% 50 mM 2-Mercaptoethanol (Merck). Tissues were then digested in
DNase I (Roche) solution and gently dissociated by pipetting. After centrifugation at 300 x g
for 5 min the supernatant was removed and the pellet resuspended and passed through a
70 μm nylon cell strainer (BD Biosciences). The single-cell suspension was seeded in poly-L-
lysine (0.1 mg/ml) (Sigma-Aldrich) precoated 75 cm2 tissue culture flasks (BD Biosciences) in
culture medium. Cells were incubated at 37°C in a 95% humidified 5% CO2 atmosphere. One
day after isolating the cells, the medium was completely replaced and cultures were kept for
another 10–14 days.
Culture and transfections of U-373 MG glioma cells
A human C/EBPD expression vector (pcMV6 human C/EBPD; SC110852, Origene) was trans-
fected into the human glioblastoma-astrocytoma cell line U-373 MG (kind gift from N. Holt-
kamp, Department of Neuropathology, Charité—Universitätsmedizin Berlin, Berlin,
Germany). 105 cells/well were transfected using Lipofectamine LTX & Plus Reagent (Life Tech-
nologies) according to the manufacturer’s protocol and incubated for 48 h.
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Statistical analysis
Results are expressed as means ± SEM. All data were analyzed for statistical significance by
two-tailed unpaired t-test using Prism 5 software (GraphPad Software Inc.). Values of p<0.05
were considered to be statistically significant.
Results
To assess the role of C/EBPD in chronic neurodegenerative diseases APP/PS1 double trans-
genic mice were compared to APP/PS1 x C/EBPD(-/-) mice. In addition, the intracerebral scra-
pie infection of wild-type C/EBPD(+/+) mice was studied in comparison to similarly infected C/
EBPD(-/-) animals.
Overall, C/EBPD(-/-) mice displayed neither in the AD nor in the prion model overt clinical
differences compared to the respective C/EBPD(+/+) controls. E.g. scrapie-infected C/EBPD(-/-)
mice developed typical clinical symptoms (weight loss, progressive ataxia, poor coat condition),
just like their wild-type counter-parts. Moreover, the survival times in both groups were virtu-
ally identical (S1 Table). Similarly, in the AD model body weights and nesting activities were
indistinguishable between both groups of mice (S1 Fig).
Table 1. Murine TaqMan assays.
Gene Symbol Assay ID Amplicon (bp) Reference sequence
Actb Mm00607939_s1 115 NM_007393.3
Iba-1 Mm00479862_g1 82 NM_019467.2
C3 Mm00437838_m1 70 NM_009778.2
Ccl3 Mm00441258_m1 78 NM_011337.2
Cd11b Mm01271259_g1 73 NM_008401.2
Cxcl2 Mm00436450_m1 67 NM_009140.2
Gapdh Mm99999915_g1 107 NM_008084.2
Gfap Mm01253033_m1 75 NM_010277.3
Il-6 Mm00446190_m1 78 NM_031168.1
Actb, beta actin; Iba-1, ionized calcium-binding adapter molecule 1; C3, complement component C3; Ccl3, chemokine (C-C motif) ligand 3; Cd11b, cluster
of differentiation molecule 11b; Cxcl2, chemokine (C-X-C motif) ligand 2, Gapdh, glyceraldehyde-3-phosphate dehydrogenase; Gfap, glial fibrillary acidic
protein; Il-6, interleukin 6
doi:10.1371/journal.pone.0134228.t001
Table 2. Human TaqMan assays.
Gene Symbol Assay ID Amplicon (bp) Reference sequence
ACTB Hs03023943_g1 122 NM_001101.3
CCL3 Hs00234142_m1 53 NM_002983.2
CP Hs00236810_m1 85 NM_000096.3
CXCL2 Hs00601975_m1 100 NM_002089.3
CXCL9 Hs00171065_m1 60 NM_002416.1
GAPDH Hs99999905_m1 122 NM_002046.3
IL-6 Hs00985639_m1 66 NM_000600.3
ACTB, beta-actin; CCL3, chemokine (C-C motif) ligand 3; CP, ceruloplasmin; CXCL2, chemokine (C-X-C motif) ligand 2; CXCL9, chemokine (C-X-C motif)
ligand; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL-6, interleukin 6
doi:10.1371/journal.pone.0134228.t002
Role of C/EBPD in AD
PLOSONE | DOI:10.1371/journal.pone.0134228 July 31, 2015 5 / 18
Next, the extent of the astro- and microgliosis in the AD and prion models was studied in
C/EBPD(-/-) and C/EBPD(+/+) mice. Astroglial GFAP and microglial Iba-1 expression was
determined by immunohistochemistry (Figs 1 and 2), by Western blot analysis as well as by
quantitative RT-PCR (S2 and S3 Figs). All animals showed typical age- and disease-related
increases of GFAP and Iba-1 expression levels over time, which were however hardly influ-
enced by the presence or absence of C/EBPD. Moreover, the mRNA expression of the micro-
glial activation marker CD11b was found to be identical in brains of APP/PS1 x C/EBPD(-/-)
and APP/PS1 x C/EBPD(+/+) animals (S10 Fig). Likewise, glia activation in scrapie-infected C/
EBPD(-/-) and wild type mice appeared to be indistinguishable (S12 Fig).
While in the prion model, PrPSc-levels in C/EBPD(-/-) mice were similar to C/EBPD(+/+)
mice (S11 Fig), immunohistochemical analysis of Abeta-immunoreactive plaques using the
6E10 antibody revealed an increased plaque burden in C/EBPD(-/-) compared to C/EBPD(+/+)
mice (Fig 3). The higher plaque load in C/EBPD-deficient mice was evident at all ages analyzed
and was most strongly pronounced in the cortex region. Staining of true amyloid plaques with
Congo red confirmed these observations (Fig 3). Amyloid plaque numbers increased over time
in cortices of mice from both groups but were significantly higher at all ages in C/EBPD-
Table 3. Mouse qRT-PCR Primer.
Gene Symbol Forward Primer 5'—-3' Reverse Primer 5'—-3' Amplicon (bp) Reference sequence
Ace1 TGGCCCAGCGGCAGCAGTA CCCTCCCAGGCAAACAACAAC 172 NM_207624.5
Actb ACTCTTCCAGCCTTCCTTC ATCTCCTTCTGCATCCTGTC 171 NM_007393.3
ApoE GAGGACACTATGACGGAAGTAAA TCTGTGCTCTGGCCCAGCATG 199 NM_009696.3
Cp GACAACACCACTGATTTTCAACGG TCTCCAGGACTTGGCTCATTGG 95 NM_007752.3
CtsB AGCCATTTCTGACCGAACCT TTGTCCAGAAGCTCCATGCT 146 NM_007798.3
Cxcl9 AAAACTGAAATCATTGCTACACTG CTCTTTTGCTTTTTCTTTTGGCTG 125 NM_008599.4
Ece1 ACACCGACAAATGTCTGCTCAA CCGTGTCACTCACACAAAACTT 168 NM_199307.2
Gapdh CCATGTTTGTGATGGGTGTGAACCA ACCAGTGGATGCAGGGATGATGTTC 251 NM_008084.2
Ide CCGGCCATCCAGAGAATAGAA ACGGTATTCCCGTTTGTCTTCA 69 NM_031156.2
Lrp1 CGCCATGGGGAAGGTGTTCTT CCCTTCGTAGTCTACCACCTCG 204 NM_008512.2
Mme CTTGTCTTGCTCCTGACTATCAT TCAAAATTACTGTATCGGGAACT 224 NM_008604.3
Ager TAGAATGGAAACTGAACACAGGA GTTAGTTGCCCGACACCGG 161 NM_007425.3
Saa3 CCAGAGAGGCTGTTCAGAAGTTCAC TCGGAAGTGGTTGGGGTCTTTG 107 NM_011315.3
Tnfaip6 CAGCTAGAGGCAGCCAGAAAA TCCATAATCGATGATACCCGTT 135 NM_009398.2
Ace1, angiotensin I-converting enzyme 1; Actb, beta-actin; ApoE, apolipoprotein E; Cp, ceruloplasmin; CtsB, cathepsin; Cxcl9, chemokine (C-X-C motif)
ligand 9; Ece1, endothelin-converting enzyme 1; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; Ide, insulin-degrading enzyme; Lrp1, low density
lipoprotein receptor-related protein 1; Mme, membrane metallo-endopeptidase; Ager, advanced glycosylation end product-specific receptor; Saa3, serum
amyloid A 3; Tnfaip6, tumor necrosis factor alpha induced protein 6
doi:10.1371/journal.pone.0134228.t003
Table 4. Human qRT-PCR primer.
Gene Symbol Forward Primer 5'—-3' Reverse Primer 5'—-3' Amplicon (bp) Reference sequence
C3 TACTACACGCTGATCGGTGC GCTTTTTACCACCAGCGAGC 102 NM_000064.2
ACTB CTGGAACGGTGAAGGTGACA AAGGGACTTCCTGTAACAATGCA 140 NM_001101.3
GAPDH TGGTATCGTGGAAGGACTCATGAC ATGCCAGTGAGCTTCCCGTTCAGC 189 NM_002046.4
TNFAIP6 TGCTGCTGGATGGATGGCTA CACTCCTTTGCGTGTGGGTT 159 NM_007115.3
ACTB, beta-actin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Tnfaip6, tumor necrosis factor alpha induced protein 6
doi:10.1371/journal.pone.0134228.t004
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Fig 1. Astrocytosis in APP/PS1 and APP/PS1 x C/EBPD(-/-) mice.Representative images showing the detection of GFAP-positive astrocytes in
hippocampi (A andB) and cortices (C andD) at 9 months of age in APP/PS1mice (A andC) and APP/PS1 x C/EBPD(-/-) mice (B andD). Quantification of
GFAP-positive astrocyte numbers in hippocampi (E) and cortices (F) over time in APP/PS1mice (n = 3; dark grey bars) and APP/PS1 x C/EBPD(-/-) mice
(n = 3; light grey bars).
doi:10.1371/journal.pone.0134228.g001
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Fig 2. Microgliosis in APP/PS1 and APP/PS1 x C/EBPD(-/-) mice.Representative images showing the detection of Iba-1-positive microglia in hippocampi
(A andB) and cortices (C andD) at 12 months of age in APP/PS1mice (A andC) and APP/PS1 x C/EBPD(-/-) mice. Quantification of Iba-1-positive cell
numbers in hippocampi (E) and cortices (F) over time in APP/PS1 mice (n = 3; dark grey bars) and APP/PS1 x C/EBPD(-/-) mice (n = 3; light grey bars).
doi:10.1371/journal.pone.0134228.g002
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Fig 3. Amyloid plaque loads in premotor cortices (M2).Representative images of amyloid plaques detected at 6 months of age using the 4G8 antibody (A
andB) or Congo red staining (C andD) in APP/PS1mice (A andC) and APP/PS1 x C/EBPD(-/-) mice (B andD). Quantification of cortical plaque loads over
time using 4G8 antibody staining (E) and Congo red staining (F) in APP/PS1mice (n = 3; dark grey bars) and APP/PS1 x C/EBPD(-/-) mice (n = 3; light grey
bars).
doi:10.1371/journal.pone.0134228.g003
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deficient animals (p<0.05; p<0.01; at 6, 9, 12 and 18 months) (Fig 3). In addition,
the amounts of total Abeta in brain homogenates from C/EBPD(-/-) and C/EBPD(+/+) mice
were assessed by Western blotting. In agreement with the plaque load data PBS- as well as for-
mic acid-extractable Abeta levels were significantly higher (p<0.05; p<0.01) in the C/EBPD(-/-)
group of mice (Fig 4).
Importantly, the higher levels of Abeta deposition in C/EBPD-deficient mice were not
attributable to an increase in APP expression (S4 Fig). In addition, mRNA expression levels of
genes known to contribute to clearance and degradation of Abeta were determined. No differ-
ences between the C/EBPD(-/-) and C/EBPD(+/+) animals were detectable concerning the
expression of neprilysin (membrane metallo-endopeptidase; MME), apolipoprotein E (Apoe),
low density lipoprotein receptor-related protein 1 (Lrp1), cathepsin B (Ctsb), endothelin-con-
verting enzyme 1 (Ece1), angiotensin I-converting enzyme (Ace), insulin-degrading enzyme
(Ide), and advanced glycosylation end product-specific receptor (Ager; formerly termed
RAGE). Hence, the increased Abeta deposition in C/EBPD(-/-) mice was not caused by alter-
ations in expression levels of genes involved in turnover or transport of Abeta (S5 Fig).
To gain more insight into C/EBPD functions in the CNS, we focused next on the expression
of candidate genes previously suggested to be regulated by the transcription factor C/EBPD in
the periphery [2, 3, 8, 10, 12, 27–29]. Moreover, these genes were selected because of their
potential participation in innate immune responses triggered by amyloid deposition in the
brain. Mixed glia cultures were established from C/EBPD(-/-) and C/EBPD(+/+) donor mice and
mRNA expression levels for a total of 8 genes were determined (Fig 5). Expression of C3 was
most strikingly affected by the absence of C/EBPD (20-fold decreased expression, p<0.01),
while for others (serum amyloid A 3 (Saa3), chemokine (C-X-C motif) ligand 9 (Cxcl9), cerulo-
plasmin (Cp)) 5.56–12.5-fold decreases (p<0.01) were observed. In addition, expression of a
further group of C/EBPD candidate target genes was more or less identical (decrease less than
2-fold) in the presence or absence of C/EBPD (chemokine (C-C motif) ligand 3 (Ccl3), Cxcl2,
tumor necrosis factor alpha induced protein 6 (Tnfaip6), interleukin 6 (Il-6)). Given that C3
mRNA levels were most clearly dependent on the presence of C/EBPD we looked in addition
for C3 protein expression by immunoblotting. In agreement with the quantitative RT-PCR
data, C3 and C3b protein was only detectable in C/EBPD(+/+) mixed glia lysates but was virtu-
ally absent in C/EBPD(-/-) cells (S6 Fig).
Expression analysis of the same genes in brains from APP/PS1 and APP/PS1 x C/EBPD(-/-)
mice confirmed that C3 mRNA levels depend on C/EBPD expression (p<0.01), but changes
for all other genes were lower than 1.5-fold and less or not significant (S7 Fig). Likewise, C3
transcript levels showed also the most pronounced differences in comparisons of mRNA levels
in scrapie-infected C/EBPD(+/+) and C/EBPD(-/-) mouse brains (S8 Fig).
Further support for the idea that C3 transcription in the CNS is indeed driven by C/EBPD
was obtained by ectopic expression of C/EBPD in the human glioblastoma cell line U-373 MG,
which expresses the astrocyte marker GFAP [30]. Upon transfection of a C/EBPD expression
vector transcript levels of the putative target genes C3, CXCL9, CCL3, and TNFAIP6 showed
very robust increases (> 5-fold) over empty control vector transfections, while others (CP and
IL-6) were less inducible (<5-fold) or even unresponsive (CXCL2) (S9 Fig).
Discussion
In the periphery the transcription factor C/EBPD acts as part of a regulatory circuit to drive
and amplify innate immune responses triggered by bacterial infections [2, 31, 32].
Chronic neurodegenerative illnesses like AD and prion diseases have a significant inflam-
matory component in part resulting from the activation of elements of the innate immunity
Role of C/EBPD in AD
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[33–35]. However, a possible involvement of C/EBPD in neuroinflammation or, more gener-
ally, in disease progression was to our knowledge as yet largely underinvestigated. We charac-
terized here mice deficient for C/EBPD to learn more about a possible role of this transcription
factor in AD and in prion diseases.
In terms of AD-like pathology the single and most profound alteration in APP/PS1 x C/
EBPD(-/-) mice compared to APP/PS1 x C/EBPD(+/+) mice was the increased plaque load at all
Fig 4. Western blot detection of Abeta in brain extracts from APP/PS1 and APP/PS1 x C/EBPD(-/-) mice. Abeta protein loads in PBS-soluble (A) and
formic acid-soluble (C) brain extracts detected using the 6E10 antibody at 9 months of age. Synthetic Abeta1-42 peptide served as additional size marker. (B
andD) Densitometric quantification of monomeric Abeta band intensities from (A) and (C), respectively (**p<0.01). Of note, the overloaded high molecular
weight material in the upper third of the gel in (A) consists of amyloid precursor protein and unspecific bands and is not relevant for the comparison of Abeta
amounts.
doi:10.1371/journal.pone.0134228.g004
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stages of the disease, which was also reflected by elevated amounts of Abeta in corresponding
brain extracts. Moreover, the significantly higher plaque load in the C/EBPD-deficient mice
was evident in immunohistochemical antibody stainings as well as in Congo red-based detec-
tion of true amyloid plaques. In contrast, the accumulation of misfolded proteinase K-resistant
prion protein PrPSc in scrapie-infected C/EBPD(-/-) mice compared to similarly infected wild-
type animals was unchanged. Therefore it seems that C/EBPD does not influence protein mis-
folding events in general but may contribute in a more specific manner to the deposition of
Abeta. Interestingly, a previous study mentioned no difference in cortical plaque numbers
between APP/PS1 x C/EBPD(-/-) and APP/PS1 x C/EBPD(+/+) mice [36]. However, given that
the underlying data have as yet not been published it is for the time being not possible to pro-
vide explanations for this potentially conflicting result.
The higher plaque load in APP/PS1 x C/EBPD(-/-) mice observed in our study was not asso-
ciated with changes concerning clinical symptoms and/or behavioral deficits. However, more
detailed studies would be needed to address possible learning and memory impairments in
these animals. In scrapie-infected mice ablation of C/EBPD had no effect on disease duration,
development of clinical symptoms, and survival times.
Theoretically, one would expect in C/EBPD-deficient mice a more pronounced gliosis in
response to the higher amyloid plaque burden. If however C/EBPD functions in part as driver
of glial activation these inflammatory glial responses would be attenuated in the absence of C/
EBPD. In terms of overall cell numbers and morphology the absence of C/EBPD had no influ-
ence on the extent of the astro- and microgliosis, which was found to be essentially identical in
C/EBPD(+/+) and C/EBPD(-/-) mice (Figs 1 and 2). Moreover, mRNA and protein expression
levels of astroglial GFAP and microglial Iba-1 were virtually identical in C/EBPD-deficient
mice compared to the controls (S2 and S3 Figs).
Of note, our results concerning the gliosis do not rule out a local reduction of glial activation
in close proximity to amyloid plaques in APP/PS1 x C/EBPD(-/-) mice [37, 38]. These findings
may indicate that glial migration is impaired in these animals. In support of this idea we show
here that C/EBPD promotes expression of the cytokines CCL3 and CXCL9 (S9 Fig). However,
our analyses of astro- and microglia activation by immunohistochemistry, Western blotting,
Fig 5. Expression of putative C/EBPD target genes in mixed glia.Gene expression levels in C/EBPD(-/-)
mixed glial cultures relative to wild type C/EBPD(++) mixed glial cultures (**p<0.01). The broken line indicates
the expression level in wild type cultures.
doi:10.1371/journal.pone.0134228.g005
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and quantitative RT-PCR clearly argue against the previously indicated possibility of a more
general attenuation of glial responses in APP/PS1 x C/EBPD(-/-) mice [37, 38].
Expression studies in cell cultures and in vivo revealed that C/EBPD may indeed play a role
in the regulation of specific glial activities. Overexpression of C/EBPD in U-373 MG cells was
previously shown to induce acute phase pentraxin-3 (Ptx-3) transcription as well as the expres-
sion of its interaction partner Tnfaip6 [10]. Ptx-3 was suggested to inhibit phagocytosis of
damaged neurons by macrophages in vitro [10]. Therefore, C/EBPD may play a role in modu-
lating inflammatory responses triggered by tissue degeneration [32, 37]. In our hands, expres-
sion of C3, Saa3, Cxcl9, Cp, and Il-6 was significantly reduced in the absence of C/EBPD in
mixed glia cultures. Vice versa, transfection of the human glioblastoma cell line U-373 MG
with a C/EBPD expression vector led to a significant upregulation of C3, CXCL9, CP, CCL3,
TNFAIP6, and IL-6 mRNA levels. C/EBPD may therefore play a role in regulating the expres-
sion of these genes in the CNS.
The example of Tnfaip6, which was found to be unaffected by C/EBPD in mixed glia cultures
but appeared to be highly responsive to C/EBPD in U-373 MG cells, illustrates that C/EBPD
functions can be cell type dependent. In addition, regulation of gene expression through C/
EBPD apparently depends on the applied type of stimulation. E.g. in LPS-stimulated mixed glia
cultures, expression of typically C/EBPD-regulated genes like IL-6 appear to be driven by other
transcription factors than C/EBPD [9]. CCAAT/enhancer-binding protein beta (C/EBPB),
which also forms heterodimers with C/EBPD, is a potential candidate in this regard [12, 39].
Among the genes studied here we found that only C3 and Saa3 mRNA levels were affected
by C/EBPD in mouse brain tissue. Transcript levels of C3 and Saa3 were significantly lower in
brain tissue from APP/PS1 x C/EBPD(-/-) mice and scrapie-infected C/EBPD(-/-) mice com-
pared to the respective controls. Of note, in the CNS both genes are typically overexpressed by
activated astrocytes [12, 40], which correlates well with the described astrocytic overexpression
of C/EBPD in AD and AD model mice [7, 10]. Hence, the evidence presented here indicates
that C/EBPD is a transcriptional regulator of the acute phase response genes C3 and Saa3 in
vivo. The observed induction of glial C3 overexpression by the pro-inflammatory cytokines IL-
1 and TNFalpha may therefore well be attributable to C/EBPD [41]. Anyhow, given that C3
and Saa3 expression was still detectable in brain tissue of C/EBPD(-/-) mice, it is clear that other
transcription factors, e.g. C/EBPB [39], can at least to some extent compensate for the absence
of C/EBPD.
A number of reports have linked complement component C3 to AD pathogenesis [42, 43].
C3 expression is upregulated in AD affected brain tissue [44, 45] and is important for the
phagocytosis and clearance of fibrillar Abeta [46, 47]. Specifically, ablation of C3 led to a signif-
icant reduction of Abeta uptake in glial cell cultures [46, 47]. Accordingly, in murine AD mod-
els inhibition of C3 activation as well as C3 a deficiency leads to increased plaque formation
[42, 43]. Thus, the reduced C3 expression levels observed in APP/PS1 x C/EBPD(-/-) mice may
well explain the higher plaque load in these animals. Reduced levels of C3 mRNA were also
observed in brain tissue from scrapie-infected C/EBPD(-/-) mice. In peripheral prion infections
a deficiency for C3 delays splenic prion accumulation and prolongs survival times [48–50].
However, while C3 promotes peripheral prion spread its role in intracerebral prion infections
is less clear [51]. We show here that a reduction of C3 levels in mice intracerebrally infected
with scrapie strain 139A has no influence on survival or deposition of misfolded prion protein
PrPSc. Given that C3 expression is clearly upregulated in prion-infected brain tissue [13, 52]
larger studies using mice with a genetic ablation of this complement component seem war-
ranted to ultimately clarify this issue.
Taken together, we show here that a C/EBPD-deficiency leads to increased Abeta plaque
burden in AD model mice. Furthermore, as shown in vivo and in vitro, C/EBPD is an
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important driver of the expression of the acute phase response genes C3 and Saa3 in the amy-
loid-affected CNS. In future work an elucidation of the pathways, which regulate C/EBPD in
response to the Abeta burden, may well help to deepen our understanding of pathomechan-
isms in fatal chronic neurodegenerative diseases like AD.
Supporting Information
S1 Fig. Development of body weights and nest building activity in the AD model. (A) Body
weights and (B) nest building activity scores of APP/PS1 mice (n = 3; dark grey circles) and
APP/PS1 x C/EBPD(-/-) mice (n = 3; light grey triangles) were monitored from 3 to 12 months
of age.
(TIF)
S2 Fig. Astrocytic GFAP expression in mouse brains (AD model). (A) Western blot detec-
tion of GFAP protein from 18-month-old APP/PS1 (n = 3) and APP/PS1 x C/EBPD(-/-) mice
(n = 4). (B) Densitometric quantification of the blot shown in (A) for APP/PS1 mice (dark
grey bars) and APP/PS1 x C/EBPD(-/-) mice (light grey bars). (C) Comparison of GFAP levels
detected by Western blotting in APP/PS1 x C/EBPD(-/-) mice relative to APP/PS1 mice at dif-
ferent time points. (D) Determination of GFAP mRNA levels in APP/PS1 x C/EBPD(-/-) mice
relative to APP/PS1 mice (n = 3).
(TIF)
S3 Fig. Microglial Iba-1 expression in mouse brains (AD model). (A) Western blot detection
of Iba-1 protein in brain homogenates from 18-month-old APP/PS1 and APP/PS1 x C/
EBPD(-/-) mice. (B) Densitometric quantification of Iba-1 levels from (A) for APP/PS1 mice
(n = 3; dark grey bars) and APP/PS1 x C/EBPD(-/-) mice (n = 4; light grey bars). (C) Compari-
son of Iba-1 levels detected by Western blotting in APP/PS1 x C/EBPD(-/-) mice relative to
APP/PS1 mice at different time points. (D) Determination of Iba-1 mRNA levels in APP/PS1 x
C/EBPD(-/-) mice relative to APP/PS1 mice (n = 3).
(TIF)
S4 Fig. APP expression in APP/PS1 and APP/PS1 x C/EBPD(-/-) mice. (A) Western blot
using brain homogenates from 9 month-old mice. (B) Densitometric quantification of APP
band intensities from (A) in APP/PS1 mice (n = 2; dark grey bars) and APP/PS1 x C/EBPD(-/-)
mice (n = 3; light grey bars).
(TIF)
S5 Fig. Brain expression levels of genes involved in Abeta transport and turnover. Relative
expression levels in APP/PS1 x C/EBPD(-/-) mice compared to APP/PS1 mice at 18 months of
age (n = 3).
(TIF)
S6 Fig. Expression of C3 and C3b protein in mixed glia obtained from C/EBPD(+/+) and C/
EBPD(-/-) mice.Western blot detection of full length C3 proteins (186.5 kDa) and cleaved C3b
fragment (102 kDa) in mixed glia cell lysates. Of note, C3 and C3b protein is hardly detectable
in C/EBPD(-/-) cell lysates.
(TIF)
S7 Fig. Brain expression of putative C/EBPD target genes (AD model). Expression levels in
APP/PS1 x C/EBPD(-/-) mice relative to APP/PS1 mice at 18 months of age (n = 3).
(TIF)
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S8 Fig. Brain expression of putative C/EBPD target genes (Prion model). Expression levels
in scrapie-infected C/EBPD(-/-) mice (n = 3) relative to similarly infected wild type mice at the
terminal stage of the disease.
(TIF)
S9 Fig. Expression of putative C/EBPD target genes in U-373MG cells transfected with a C/
EBPD expression vector. Expression levels shown are relative to empty vector control trans-
fections. Of note, expression of the human SAA3 gene was not included in this experiment
because it is considered to be a non-functional, non-transcribed pseudogene (Kluve-Becker-
man B, DrummML, Benson MD. Nonexpression of the human serum amyloid A three
(SAA3) gene. DNA Cell Biol. 1991;10(9):651–61. PubMed PMID: 1755958).
(TIF)
S10 Fig. CD11b mRNA levels in brain homogenates. Determination of CD11b mRNA levels
in APP/PS1 x C/EBPD(-/-) mice (n = 3) relative to APP/PS1 mice (n = 3).
(TIF)
S11 Fig. Western blot detection of proteinase K resistant PrPSc in brain extracts from scra-
pie-infected wild type C/EBPD(+/+) and C/EBPD(-/-) mice. (A) Western blot from scrapie-
infected C/EBPD(+/+) (n = 3) and C/EBPD(-/-) mice (n = 3) at the terminal stage of the disease.
(B) Densitometric quantification of staining intensities.
(TIF)
S12 Fig. Astrocytosis and microgliosis in scrapie-infected wild type C/EBPD(+/+) and C/
EBPD(-/-) mice. Representative images showing GFAP-positive astrocytes (A and B) and Iba-
1-positive microglia (C andD) at 125 dpi in hippocampi of scrapie-infected wild type C/
EBPD(+/+) (A and C) and C/EBPD(-/-) mice (B andD). Quantification of GFAP-positive astro-
cytes (E) and Iba-1-positive microglia (F) at 125 dpi in wild type C/EBPD(+/+) mice (n = 4;
dark grey bars) and C/EBPD(-/-) mice (n = 4; light grey bars).
(TIF)
S1 Table. Survival times (Prion model). Survival times of scrapie-infected wild type C/EBPD(-
+/+) (n = 9) and C/EBPD(-/-) mice (n = 9).
(TIF)
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